Document is current

Article History

Received: 8 November 2022

Accepted: 20 January 2023

First Online: 23 February 2023

Declarations

:

: CM reports research cooperation with the University of Würzburg and Tomtec Imaging Systems funded by a research grant from the Bavarian Ministry of Economic Affairs, Regional Development and Energy, Germany; advisory and speakers honoraria as well as travel grants from Amgen, Tomtec, Orion Pharma, Alnylam, AKCEA, Pfizer, Boehringer Ingelheim, SOBI, Alexion, Janssen, and EBR Systems; principal investigator in trials sponsored by Alnylam, Bayer and AstraZeneca; financial support from the interdisciplinary center for clinical research—IZKF Würzburg (advanced clinician-scientist program). AP received research funding grand from Pfizer, consulting fees from Pfizer, Alnylam, Aksea and Swedish Orphan Biovitrum GmbH-Sobi, financial support for attending meetings and/or travel from Alnylam, Akcea and Pfizer. Aikaterini Papagianni is also PI in ION-682884-CS3 study. SI received financial reimbursement for consulting, advisory board activities, speaker honoraries and/or travel support to attend scientific meetings by Akcea Therapeutics Inc., Alnylam Pharmaceuticals Inc., Pfizer Pharmaceuticals, Janssen-Cilag GmbH, and Takeda, and further research funding from Pfizer Pharmaceuticals and Akcea Therapeutics Inc.. An internship was supported by ONLUS. She was fellow of the local Clinician Scientist program of the IZKF Würzburg. VC received financial support and travel funding for attendance of scientific congresses from Alnylam Pharmaceuticals Inc. and Boehringer Ingelheim. StS is supported by the CHFC Würzburg, and by the German Federal Ministry of Education and Research (BMBF). He has received consultancy and lecture fees as well as reimbursement of travel costs from AstraZeneca, Bayer, Boehringer Ingelheim, Novartis, Pfizer, and Servier. The other authors report no conflict of interest.